Staab H J, Ahlemann L M, Anderer F A, Hiesche K, Rodatz W
J Clin Chem Clin Biochem. 1981 Jun;19(6):339-45. doi: 10.1515/cclm.1981.19.6.339.
Using commercially available radioimmune test kits, serial determinations of serum beta 2-microglobulin and CEA were performed in 337 patients, who had been treated for breast cancer by modified radical mastectomy and radiotherapy. The pre-therapeutic data indicated a higher incidence of pathological beta 2-microglobulin and CEA levels in patients with distant metastases than in patients with localized disease. However, this finding did not allow the conclusion of a direct complementarity of beta 2-microglobulin and CEA as tumour markers, since the group of patients with distant metastasis contained a high percentage of elderly patients who generally can be expected to have elevated beta 2-microglobulin serum concentrations. Therefore, the correlation of the clinical course of malignant disease and the incidence of relapses with the changes of serum beta 2-microglobulin and CEA concentrations was examined during the post-treatment surveillance: 7/9 cases (78%) with local recurrence and 46/73 cases (63%) with distant spread of disease were not indicated in the beta 2-microglobulin follow-up by pathologic serum concentrations, whereas in the CEA follow-up only 1/9 and 2/73 false negative indications were registered. The poor correlation suggests that serum beta 2-microglobulin is not directly tumour associated in breast cancer and does not fulfill the criteria of a tumour marker.
使用市售的放射免疫检测试剂盒，对337例接受改良根治性乳房切除术和放射治疗的乳腺癌患者进行了血清β2-微球蛋白和癌胚抗原的系列测定。治疗前的数据表明，远处转移患者的病理性β2-微球蛋白和癌胚抗原水平发生率高于局限性疾病患者。然而，这一发现并不能得出β2-微球蛋白和癌胚抗原作为肿瘤标志物具有直接互补性的结论，因为远处转移患者组中老年患者的比例很高，而老年患者通常预期其血清β2-微球蛋白浓度会升高。因此，在治疗后监测期间，研究了恶性疾病的临床病程和复发率与血清β2-微球蛋白和癌胚抗原浓度变化之间的相关性：9例局部复发患者中有7例（78%），73例疾病远处转移患者中有46例（63%），在β2-微球蛋白随访中，病理血清浓度未显示异常，而在癌胚抗原随访中，仅记录到1/9和2/73的假阴性结果。这种较差的相关性表明，血清β2-微球蛋白在乳腺癌中并非直接与肿瘤相关，不符合肿瘤标志物的标准。
